Skip to main content
Give ‘em L: Patient support. Novartis Patient Support

$0 Co-pay Savings

86% of the commercial patients who utilized the LEQVIO® Co-pay Program paid $01

Your eligible patients with commercial insurance may pay as little as $0.

No financial information required. Subject to terms and conditions. Limitations apply.*

If coverage is delayed or denied for commercial patients, reach out to the LEQVIO® Service Center for more information on patient affordability support options. 

Enroll your commercial patients and submit and manage co-pay claims for reimbursement

Patients can directly enroll in co-pay services by signing up viaStart.LEQVIO.com or by calling 833-LEQVIO2 (833-537-8462) .

Looking for additional assistance?

For additional patient access support including benefits verification, enroll your patients via our LEQVIO Service Center by completing and faxing thestart form or signing up via ourfull-service portal .

*Limitations apply. Valid only for those with commercial insurance. The Program may include the Co-pay Card, Payment Card (if applicable), and Rebate. Per-treatment maximums and an annual benefit cap apply. For patients covered under the medical benefit, rebate for out-of-pocket costs will be assigned directly to provider, unless patient requests direct reimbursement. Patient is responsible for any costs once limit is reached in a calendar year. Program not valid (i) under Medicare, Medicaid, TRICARE, VA, DoD, or any other federal or state health care program, (ii) where patient is not using insurance coverage at all, (iii) where the patient’s insurance plan reimburses for the entire cost of the drug, or (iv) where product is not covered by patient’s insurance. The value of this program is exclusively for the benefit of patients and is intended to be credited towards patient out-of-pocket obligations and maximums, including applicable co-payments, coinsurance, and deductibles. Program is not valid where prohibited by law. Patient may not seek reimbursement for the value received from this program from other parties, including any health insurance program or plan, flexible spending account, or health care savings account. Patient is responsible for complying with any applicable limitations and requirements of their health plan related to the use of the Program. Valid only in the United States and Puerto Rico. This Program is not health insurance. Program may not be combined with any third-party rebate, coupon, or offer. Proof of purchase may be required. Novartis reserves the right to rescind, revoke, or amend the Program and discontinue support at any time without notice.

All trademarks are the property of their respective owners.

LEQVIO® Care Program

Patients can enroll in dedicated phone support from the LEQVIO Care Program—an optional program to help patients start and stay on track with their treatment plan. When enrolled, patients on therapy have access to:

  • One-on-one support by dedicated specialists
  • Injection appointment reminders
  • Helpful tools, lifestyle tips, and motivation through text, mail, and email

For more information, visit the Patient Site

Patients can enroll directly by visiting Start.LEQVIO.com or by calling 833-LEQVIO2 (833-537-8462).

The LEQVIO Care Program is a patient support program and is not intended to take the place of medical or clinical advice from a health care provider.

LDL-C, low-density lipoprotein cholesterol.

Fill out the Patient Start Form

Download and fax our single-page Patient Start Form to 1-877-LEQVIO8 (1-877-537-8468)

Enroll online

Enroll your patients electronically for all services, including the LEQVIO Co-pay Program

Leqvio Patient Brochure.

Looking for more information for your patients?

Leqvio patient brochure in Spanish

Looking for more information for your patients?

LEQVIO patient website

Explore the LEQVIO Patient Website

There's more to know about LEQVIO

Discover supportive resources available to help your patients get started on LEQVIO to help reduce LDL-C

Reference: 1. Data on file. LEQVIO Coverage and Affordability. Novartis Pharmaceuticals Corp; 2024.